psoriasis

Amgen ramps up Otezla expansion effort with positive data in mild psoriasis
Amgen ramps up Otezla expansion effort with positive data in mild psoriasis
Fierce Pharma
Amgen
Celgene
Otezla
psoriasis
Flag link:
Lilly spends big on mirikizumab
Lilly spends big on mirikizumab
EP Vantage
Eli Lilly
mirikizumab
psoriasis
clinical trials
Flag link:
AbbVie Reports Successful Trial Results for Arthritis Drug
AbbVie Reports Successful Trial Results for Arthritis Drug
Motley Fool
AbbVie
Rinvoq
Upadacitinib
psoriasis
clinical trials
Flag link:
AbbVie and Boehringer Ingelheim's Skyrizi Beat Novartis' Cosentyx in Plaque Psoriasis
AbbVie and Boehringer Ingelheim's Skyrizi Beat Novartis' Cosentyx in Plaque Psoriasis
Motley Fool
AbbVie
Boehringer Ingelheim
Skyrizi
Novartis
Cosentyx
psoriasis
Flag link:
Durect shares rocked by midstage psoriasis flop, shifts focus to liver disease
Durect shares rocked by midstage psoriasis flop, shifts focus to liver disease
Fierce Biotech
Durect
clinical trials
psoriasis
DUR-928
Flag link:
UCB posts more supportive data from Humira rival bimekizumab
UCB posts more supportive data from Humira rival bimekizumab
Pharmaforum
UCB Pharma
bimekizumab
AbbVie
Humira
psoriasis
biosimilars
Flag link:
Amgen juices up sales outlook amid high hopes for Celgene castoff Otezla
Amgen juices up sales outlook amid high hopes for Celgene castoff Otezla
Fierce Pharma
Amgen
Otezla
Celgene
psoriasis
Flag link:
UCB adds on more positive PhIII data for IL-17A/17F inhibitor bimekizumab, clearing a path to the FDA
UCB adds on more positive PhIII data for IL-17A/17F inhibitor bimekizumab, clearing a path to the FDA
Endpoints
UCB Pharma
bimekizumab
psoriasis
clinical trials
Flag link:
Johnson & Johnson's Tremfya backs psoriatic arthritis play with newest data
Johnson & Johnson's Tremfya backs psoriatic arthritis play with newest data
Fierce Pharma
JNJ
Tremfya
psoriatic arthritis
psoriasis
clinical trials
Flag link:
J&J’s Tremfya Shows Extended Success in Treating Plaque Psoriasis
J&J’s Tremfya Shows Extended Success in Treating Plaque Psoriasis
BioSpace
JNJ
Janssen
Tremfya
clinical trials
psoriasis
Flag link:
UCB's bispecific beats J&J's Stelara in psoriasis phase 3
UCB's bispecific beats J&J's Stelara in psoriasis phase 3
Fierce Biotech
UCB Pharma
bispecific antibodies
bimekizumab
JNJ
Stelara
psoriasis
Flag link:
UCB tries to win some respect in the crowded psoriasis market with a dual IL-17 approach — and it won't be easy
UCB tries to win some respect in the crowded psoriasis market with a dual IL-17 approach — and it won't be easy
Endpoints
UCB Pharma
Amgen
psoriasis
bimekizumab
Flag link:
Sienna Biopharmaceuticals Files for Bankruptcy, Delaying Phase III Psoriasis Trial
Sienna Biopharmaceuticals Files for Bankruptcy, Delaying Phase III Psoriasis Trial
BioSpace
Sienna Biopharmaceuticals
bankruptcy
psoriasis
SNA-120
Flag link:
Skyrizi looks ready to soar after strong launch
Skyrizi looks ready to soar after strong launch
Biopharma Dive
AbbVie
Skyrizi
psoriasis
Flag link:
Celgene sells psoriasis pill to Amgen for $13.4 billion, clearing way for close of Bristol merger
Celgene sells psoriasis pill to Amgen for $13.4 billion, clearing way for close of Bristol merger
Stat
Amgen
Otezla
Celgene
M&A
Bristol-Myers Squibb
psoriasis
Flag link:
5 Biggest New Drugs Approved in 2019 So Far
5 Biggest New Drugs Approved in 2019 So Far
Motley Fool
drug approvals
FDA
AbbVie
JNJ
Novartis
Pfizer
Skyrizi
psoriasis
Vyndaqel
Zolgensma
SMA
Mayzent
multiple sclerosis
Balversa
metastatic bladder cancer
Flag link:
Eli Lilly's Taltz bests J&J rival Tremfya in head-to-head psoriasis tilt
Eli Lilly's Taltz bests J&J rival Tremfya in head-to-head psoriasis tilt
Fierce Pharma
Eli Lilly
Taltz
JNJ
Tremfya
psoriasis
Flag link:
AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib
AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib
Fierce Pharma
AbbVie
Humira
biosimilars
Europe
psoriasis
rheumatoid arthritis
Skyrizi
Flag link:
Eli Lilly's Taltz touts long-term clear skin data after unimpressive first-quarter sales
Eli Lilly's Taltz touts long-term clear skin data after unimpressive first-quarter sales
Fierce Pharma
Eli Lilly
Taltz
psoriasis
Flag link:
Ramaswamy's Dermavant Updates $124 Million IPO Filing
Ramaswamy's Dermavant Updates $124 Million IPO Filing
CP Wire
Dermavant
IPOs
tapinarof
psoriasis
dermatitis
Vivek Ramaswamy
Flag link:

Pages